Compare Procter & Gamble Co (PG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Travere Therapeutics Inc. Common Stock — how do they compare? Procter & Gamble Co trades at $157.15 (market cap $355.46B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Procter & Gamble Co is far larger — about 72.8× Travere Therapeutics Inc. Common Stock's market cap, and Procter & Gamble Co pays a 2.85% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Procter & Gamble Co for 132 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PG | TVTX | |
|---|---|---|
Market Cap | $355.46B | $4.88B |
Volume | 5,731,171 | 1,668,577 |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $67.52 |
52-Week Low | $138.10 | $26.79 |
Typical Hold Time | 132 Days | 0 Days |
Enterprise Value | $381.30B | $5.01B |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $156.57, up 2.2% today, near its consensus price target of $160.13. The stock shows bullish technical signals with strong moving average support and has beaten earnings estimates for three consecutive quarters. Revenue reached $84.28B in 2025 with a net income margin of 18.44%, while the company maintains a robust dividend history and positive cash flow trends.
PG offers stable growth with high profitability and shareholder returns, but premium valuation multiples pose near-term upside limitations. Risks include soft demand outlook and competitive pressures, though analyst consensus remains bullish with 53% buy ratings. The stock's resilience in volatile markets supports its appeal for dividend-focused investors.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
